EirGen Pharma Oncology Product Eir-045 submitted in US

EirGen Pharma are pleased to announce that their oncology molecule "Eir-045" was submitted to the Food & Drug Administration (FDA) in January 2010. This product was developed as an adjuvant treatment of postmenopausal women with estrogen-receptor postive early breast cancer and successfully passed fed & fasted clinical trial studies in 2009. Company Co-Founder and Technical Director Tom Brennan commented "This marks another key milestone for our organisation as the fifth US FDA application for our organisation and is a tremendous start to 2010".

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility, the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.